Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor.

[1]  Jianguo Fang,et al.  Sanguinarine as a new chemical entity of thioredoxin reductase inhibitor to elicit oxidative stress and promote tumor cell apoptosis. , 2020, Free radical biology & medicine.

[2]  W. Peng,et al.  Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer , 2019, Scientific Reports.

[3]  Yi Luo,et al.  Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways. , 2019, Biochemical pharmacology.

[4]  Xi Xu,et al.  Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer. , 2019, European journal of medicinal chemistry.

[5]  M. Wangpaichitr,et al.  Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer , 2019, Molecular Cancer Research.

[6]  Chao Zhang,et al.  Piperlongumine Inhibits Akt Phosphorylation to Reverse Resistance to Cisplatin in Human Non-Small Cell Lung Cancer Cells via ROS Regulation , 2019, Front. Pharmacol..

[7]  Zhiyu Li,et al.  Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO. , 2019, Biochemical pharmacology.

[8]  F. Pan,et al.  Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments , 2019, BioMed research international.

[9]  Wukun Liu,et al.  Targeting the Thioredoxin System as a Strategy for Cancer Therapy. , 2019, Journal of medicinal chemistry.

[10]  Md. Arafat Hussain,et al.  Tryptophan-kynurenine pathway attenuates β-catenin-dependent pro-parasitic role of STING-TICAM2-IRF3-IDO1 signalosome in Toxoplasma gondii infection , 2019, Cell Death & Disease.

[11]  Xiao Han,et al.  Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: An update , 2019, Medicinal research reviews.

[12]  Xi Xu,et al.  Palladium(II)-Catalyzed Reaction of Lawsones and Propargyl Carbonates: Construction of 2,3-Furanonaphthoquinones and Evaluation as Potential Indoleamine 2,3-Dioxygenase Inhibitors. , 2018, The Journal of organic chemistry.

[13]  D. Wainwright,et al.  IDO1 in cancer: a Gemini of immune checkpoints , 2018, Cellular & Molecular Immunology.

[14]  Xiao Han,et al.  Targeting the Thioredoxin System for Cancer Therapy. , 2017, Trends in pharmacological sciences.

[15]  Eng-Hui Chew,et al.  Design, Synthesis, and Biological Evaluation of Coupled Bioactive Scaffolds as Potential Anticancer Agents for Dual Targeting of Dihydrofolate Reductase and Thioredoxin Reductase. , 2017, Journal of medicinal chemistry.

[16]  P. Zou,et al.  Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer. , 2016, Cancer letters.

[17]  Sun Mi Gu,et al.  Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway , 2016, Scientific Reports.

[18]  Su-Ying Wu,et al.  Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1. , 2016, Journal of medicinal chemistry.

[19]  D. Tweardy,et al.  Piperlongumine Blocks JAK2-STAT3 to Inhibit Collagen-Induced Platelet Reactivity Independent of Reactive Oxygen Species† , 2015, PloS one.

[20]  P. Verhoest,et al.  Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway. , 2015, Journal of medicinal chemistry.

[21]  Bo Zhou,et al.  Development and mechanism investigation of a new piperlongumine derivative as a potent anti-inflammatory agent. , 2015, Biochemical pharmacology.

[22]  Zhiyu Li,et al.  Research progress of indoleamine 2,3-dioxygenase inhibitors. , 2015, Future medicinal chemistry.

[23]  Y. Chao,et al.  Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[24]  T. MacDonald,et al.  The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma , 2014, Journal of Immunotherapy for Cancer.

[25]  Jianguo Fang,et al.  Dithiaarsanes induce oxidative stress-mediated apoptosis in HL-60 cells by selectively targeting thioredoxin reductase. , 2014, Journal of medicinal chemistry.

[26]  Jianguo Fang,et al.  Highly selective off-on fluorescent probe for imaging thioredoxin reductase in living cells. , 2014, Journal of the American Chemical Society.

[27]  C. Piccirillo,et al.  Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives , 2011, Clinical Cancer Research.

[28]  M. Baccarani,et al.  Tolerance: Focus on Hematology the Role of Indoleamine 2,3-dioxygenase in the Induction of Immune , 2008 .

[29]  R. Pellicciari,et al.  Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease , 2009, Amino Acids.

[30]  Judith M. LaLonde,et al.  Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. , 2008, Journal of medicinal chemistry.

[31]  V. Gladyshev,et al.  Targeting Thioredoxin Reductase 1 Reduction in Cancer Cells Inhibits Self-Sufficient Growth and DNA Replication , 2007, PloS one.

[32]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[33]  V. Gladyshev,et al.  Thioredoxin Reductase 1 Deficiency Reverses Tumor Phenotype and Tumorigenicity of Lung Carcinoma Cells* , 2006, Journal of Biological Chemistry.

[34]  Takashi Otsuki,et al.  Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Kikuya Kato,et al.  High Thioredoxin Expression Is Associated with Resistance to Docetaxel in Primary Breast Cancer , 2005, Clinical Cancer Research.

[36]  Qiong Liu,et al.  Inhibitory effects of thioredoxin reductase antisense RNA on the growth of human hepatocellular carcinoma cells , 2005, Journal of cellular biochemistry.

[37]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[38]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[39]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[40]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[41]  Shozo Yamamo.  Tryptophan Pyrrolase of Rabbit Intestine , 2003 .